Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Congratulations to the #C4XD team getting their first £3m milestone payment from #sanofi. Life Science, especially the Biotech development side can be a tough business, but validation like this makes the tough times worth it.
Starting to rise again. Expectation of sanofi milestone payment very soon now
Yes a good article DD77. Would be interesting to know the future timelines for receipt of the subsequent milestone payments from Sanofi and AZ.
I Googled Sanofi's pipeline of drugs under research and development but could not locate the one that Sanofi made the payment to C4X for. However, they could be calling it by some other biopharma description. Not being a chemist, all double Dutch to me!
Good write up and interview. Worth a read
https://www.proactiveinvestors.co.uk/companies/news/1038104/c4xd-a-biotechnology-pioneer-in-immuno-inflammation-1038104.html
First time poster, on verge of retiring and going to spend more time of my hobby, in investing in early stage companies, with growth prospects.
The correction in the share price today, I do not believe is down to I institutional investors taking profits, as one poster indicated. I cannot see II's selling off such small amounts of stock. More like private investors seeing the share price slightly falling, worrying and joing the herd, making the price drop more than it might have been. In other words, taking the short term speculative view.
Taking the longer view, when the next interim accounts and full YE results come out, readers should hopefully see:
- total income in previous financial year: £1.7m
-without any further income from now, income on a comparable basis, will include Invidior £15.95m and
Astra Zeneca $11m.
That comparison in itself will attract attention, although sales are not profit.
Even if cost of sales and overheads are similar to previous year, this would indicate positive EBIT being the result.
There will be minimal, if nil debt. Another tremendous positive in the current interest rate environment.
Even if company continues to burn cash with further R and D on new innovative solutions for medical conditions, at the same level as last year, I believe should be more than enough cash in bank for circa eighteen months to two years, even without any additional interim milestone payments from Sanofi or AZ, that may be received.
As previous contributors have already mentioned, there could be interest from larger biopharm entities in this little company.
In summary, one in my view to have in your portfolio for the long term (but not for widows/widowers or orphans) , as long as you can ride out the roller coaster ride!
Absolutely spot on Newuncle. Today has been an opportunity...again
No, it's PIs being scared into selling their shares to keep their profits before they get taken away by MMs looking for shares for the next leg up.
Now trading at pretty much cash again.
Did they have to give back their research money...lol
Share price is taking a tumble...
Recent Developments
Last Updated: 03/01/2024
C4XD announced a significant ($11m) milestone payment from AstraZeneca on 3 January, under a licensing deal with Astra Zeneca, signed in November 2022. Under the agreement, AstraZeneca received an exclusive global licence for the NRF2 Activator programme. In return, C4XD received a $2m upfront payment and is eligible for pre-clinical milestone payments totalling $14m and a further $386m in clinical and commercial milestone payments. AstraZeneca are developing the drug as a treatment for a number of inflammatory conditions and the market for these is worth $60bn. The category includes Sickle Cell Disease, IBD and lung diseases such as COPD. We shall be meeting the CEO later in January.
It's "UP TO"
Just to add that they 2 of these arrangements in place, second is with sanofi. Same numbers but in euros not dollars.
So C4X Discovery Holdings plc received a USD11.0 million milestone payment from FTSE 100-listed pharmaceutical firm AstraZeneca PLC, following trials of the C4X respiratory disease therapy treatment. The payment stems from preclinical progress of C4X's NRF2 Activator programme, an oral therapy for the treatment of inflammatory and respiratory diseases which AstraZeneca is developing following a agreement between the two in November. In addition to a USD2.0 million upfront payment, the global licencing agreement for the NRF2 Activator entitles C4X to receive up to USD400.0 million in payments following preclinical, clinical development and commercial milestones. The deal also will grant C4X tiered mid-single digit royalties on future sales of the NRF2.
This share is so undervalued now, so can't wait to top up on my holding ! There does not appear to be a better investment out there except maybe Futura Medical. Perhaps split any available monies between both of these.
I saw the below post by gggg21 , I have to many losing AIM shares , I have read on other BBs that you can not go short on these types of shares , and this one having a smaller free float then others .
What is the truth of shorting on AIM .
RE: So...15 Dec 2023 08:10
Amazing how that one short opened this morning has pushed it down but so difficult to buy.
Up 13% to 17.3p on the bid. 2.9% spread the ask is 17.8p.
Now above my buy price of 16.65p in hindsight the noticed 43% rise two days ago was a buy signal .
Two weeks ago on 18/12/23 I saw a new low of 8.41p ( 50 % down ) must be manipulation this payment was known to be coming ?
Bad luck for any who might of sold a week before Christmas day.
Thanks for sharing.
I concur that this rise is more than just reassurance on funding requirements - it is further validation of the tech, and an important value inflection point. The 3 days of consecutive strong SP rises on heavy trading demonstate that.
With a Sanofi milestone payment imminent and further deals in the pipeline, I expect a big 2024. This was above 40p a couple of years ago. I expect it to rise significantly above that
It’s fair to say C4X Discovery had a fantastic start with the shares advancing 113 per cent over the foreshortened trading week after drug giant AstraZeneca delivered an $11million post-Christmas windfall.
It came in the form of what the experts call a ‘milestone payment’ under a $402million deal with Anglo-Swedish giant, which has licensed the right to NRF2 activator, created by C4XD to tackle chronic respiratory disease.
Analysts said the payment went further than adding a material sum to the AIM company’s coffers – it provided third-party validation of the technology.
'We see this as an important value inflexion which should reinvigorate sentiment in the share,' said regional broker Shore Capital.
'Moreover, this serves as a timely reminder that C4XD has licensing deals in place with some of the leading developers for its programmes.'
https://www.thisismoney.co.uk/money/markets/article-12930315/SMALL-CAP-MOVERS-C4X-Discovery-cashes-deal-pharma-giant.html
Still got a lot higher to go though, thats my view anyway...gla
"It's dollars not £s"
It's $s and €s - not £s.
Lombard is simply risk managing their investment after a decent rise...it's common amongst fund managers...
either way, the pharma sector's on the turn at last so bullishness is returning to a battered sector
If they are still selling, it's getting snapped up. This doesn't half shoot due to the small free float. My average of 24p now within sight
Don't know why Lombard sold yesterday,
looking good though
Before the next news and next leg up ?
Looks like they are still selling
Going to be a lot of good sessions ahead as it heads to over 1.20 and beyond
GLA